Analyst Price Target is $29.00
▲ +28.04% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for R1 RCM in the last 3 months. The average price target is $29.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 28.04% upside from the last price of $22.65.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in R1 RCM. This Buy consensus rating has held steady for over two years.
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Murray, Utah.